✦ LIBER ✦

Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease

✍ Scribed by Margaret M. Maier Hoehn

Book ID: 114782107
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 619 KB
Volume: 71
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1985.tb03173.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early combination therapy with bromocrip

Early combination therapy with bromocriptine and levodopa in parkinson's disease

✍ Dr. Stewart A. Factor; William J. Weiner 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 588 KB

## Abstract The use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a stand

Mutual interaction of bromocriptine and

Mutual interaction of bromocriptine and levodopa in the periphery in Parkinson's disease

✍ J.M. Rabey; Z. Oberman; A. Harsat; E. Graff; Y. Vered 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Modification of central dopaminergic mec

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

✍ Dr; MD M. Maral Mouradian; MD Isabella J. E. Heuser; MD Fabio Baronti; MD Thomas 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 568 KB

Bromocriptine blood levels after the con

Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease

✍ J. M. Rabey; Z. Oberman; M. Scharf; M. Isakov; M. Bar; E. Graff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB

Time course of loss of clinical benefit

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

✍ Robert A. Hauser; William C. Koller; Jean P. Hubble; Teresita Malapira; Karen Bu 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

Quantitative description of loss of clin

Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

✍ Robert A. Hauser; Nicholas H.G. Holford 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

## Abstract In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient d